Terms: = Prostate cancer AND NCOA2, TIF2, 10499, ENSG00000140396, NCoA-2, MGC138808
55 results:
1. Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.
Haldrup J; Weiss S; Schmidt L; Sørensen KD
Sci Rep; 2023 Jun; 13(1):9043. PubMed ID: 37270558
[TBL] [Abstract] [Full Text] [Related]
2. Qingdai Decoction suppresses prostate cancer growth in lethal-stage prostate cancer models.
Chen Y; Zhou Q; Zhang H; Xu L; Lu L; Shu B; Zhou L; Yuan F
J Ethnopharmacol; 2023 May; 308():116333. PubMed ID: 36863640
[TBL] [Abstract] [Full Text] [Related]
3. African-specific molecular taxonomy of prostate cancer.
Jaratlerdsiri W; Jiang J; Gong T; Patrick SM; Willet C; Chew T; Lyons RJ; Haynes AM; Pasqualim G; Louw M; Kench JG; Campbell R; Horvath LG; Chan EKF; Wedge DC; Sadsad R; Brum IS; Mutambirwa SBA; Stricker PD; Bornman MSR; Hayes VM
Nature; 2022 Sep; 609(7927):552-559. PubMed ID: 36045292
[TBL] [Abstract] [Full Text] [Related]
4. Independent prognostic impact of plasma ncoa2 alterations in metastatic castration-resistant prostate cancer.
Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
[TBL] [Abstract] [Full Text] [Related]
5. NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population.
Ramanayake N; Vargas AC; Talbot J; Bonar F; Wong DD; Wong D; Mahar A; Karim R; Luk PP; Selinger C; Sioson L; Gill AJ; Maclean F
Pathology; 2021 Oct; 53(6):705-712. PubMed ID: 33640159
[TBL] [Abstract] [Full Text] [Related]
6. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive prostate cancer.
Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ
Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031
[TBL] [Abstract] [Full Text] [Related]
7. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
Fancher AT; Hua Y; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
[TBL] [Abstract] [Full Text] [Related]
8. [Mining and discovery for active components of "Coptidis Rhizome-Magnoliae Officinalis Cortex" based on network pharmacology].
Wu HN; Yu GH; Zhao FZ; Jia XB; Feng L; Shi XH
Zhongguo Zhong Yao Za Zhi; 2019 Feb; 44(4):803-810. PubMed ID: 30989895
[TBL] [Abstract] [Full Text] [Related]
9. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of prostate cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract] [Full Text] [Related]
10. High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.
Hua Y; Camarco DP; Strock CJ; Johnston PA
Methods Mol Biol; 2018; 1683():211-227. PubMed ID: 29082495
[TBL] [Abstract] [Full Text] [Related]
11. SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer.
Suresh S; Durakoglugil D; Zhou X; Zhu B; Comerford SA; Xing C; Xie XJ; York B; O'Donnell KA
PLoS Genet; 2017 Mar; 13(3):e1006650. PubMed ID: 28273073
[TBL] [Abstract] [Full Text] [Related]
12. Reconfiguring the AR-tif2 Protein-Protein Interaction HCS Assay in prostate cancer Cells and Characterizing the Hits from a LOPAC Screen.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2016 Oct; 14(8):453-477. PubMed ID: 27606620
[TBL] [Abstract] [Full Text] [Related]
13. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract] [Full Text] [Related]
14. ncoa2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
[TBL] [Abstract] [Full Text] [Related]
15. Bone stroma-derived cells change coregulators recruitment to androgen receptor and decrease cell proliferation in androgen-sensitive and castration-resistant prostate cancer cells.
Villagran MA; Gutierrez-Castro FA; Pantoja DF; Alarcon JC; Fariña MA; Amigo RF; Muñoz-Godoy NA; Pinilla MG; Peña EA; Gonzalez-Chavarria I; Toledo JR; Rivas CI; Vera JC; McNerney EM; Onate SA
Biochem Biophys Res Commun; 2015 Nov; 467(4):1039-45. PubMed ID: 26494300
[TBL] [Abstract] [Full Text] [Related]
16. MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
Nilsson EM; Laursen KB; Whitchurch J; McWilliam A; Ødum N; Persson JL; Heery DM; Gudas LJ; Mongan NP
Oncotarget; 2015 Nov; 6(34):35710-25. PubMed ID: 26461474
[TBL] [Abstract] [Full Text] [Related]
17. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis.
Dasgupta S; Putluri N; Long W; Zhang B; Wang J; Kaushik AK; Arnold JM; Bhowmik SK; Stashi E; Brennan CA; Rajapakshe K; Coarfa C; Mitsiades N; Ittmann MM; Chinnaiyan AM; Sreekumar A; O'Malley BW
J Clin Invest; 2015 Mar; 125(3):1174-88. PubMed ID: 25664849
[TBL] [Abstract] [Full Text] [Related]
18. Androgen deprivation-induced ncoa2 promotes metastatic and castration-resistant prostate cancer.
Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
[TBL] [Abstract] [Full Text] [Related]
19. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Hua Y; Shun TY; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
[TBL] [Abstract] [Full Text] [Related]
20. Biological correlates of prostate cancer perineural invasion diameter.
Olar A; He D; Florentin D; Ding Y; Wheeler T; Ayala G
Hum Pathol; 2014 Jul; 45(7):1365-9. PubMed ID: 24768607
[TBL] [Abstract] [Full Text] [Related]
[Next]
